All In Biotech

Drug Trial Radar · NCT00940498

Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors

A Phase 1 Study Of Pf-05212384 (Also Known As Pki-587) Administered As An Intravenous Infusion To Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

78

Actual

Start

Jan 2010

Primary completion

Aug 2011

Study completion Oct 2012

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment Method (CRM). Part 1 will include subjects with any solid tumor. In Part 2 two cohorts will be enrolled. One cohort will assess safety, tolerability and preliminary efficacy in 20 subjects at the MTD and will include subjects with breast cancer, ovarian cancer, endometrial cancer, colorectal cancer renal cancer or glioblastoma (a type of brain tumor). The other cohort will include 5 to 15 subjects with any type of tumor who consent to provide tumor biopsies while participating in the study.

Conditions

  • Neoplasms

Interventions

  • PF-05212384 (also known as PKI-587)Drug

    Intravenous dosing once weekly infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)Time frame: Baseline up to Cycle 14 (each cycle is 28 days)
  2. Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)Time frame: Baseline up to Cycle 14 (each cycle is 28 days)
  3. Number of Participants With Laboratory AbnormalitiesTime frame: Baseline up to Cycle 14 (each cycle is 28 days)
  4. Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Baseline up to Day 28
  5. Recommended Phase-2 Dose (RP2D)Time frame: Baseline up to Cycle 14 (each cycle is 28 days)

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Insitute

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Sarah Cannon Research Institute, Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Hospital General Vall D'Hebron

    Barcelona, Spain

  • King's College London

    London, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.